Skip to main content
. Author manuscript; available in PMC: 2018 Feb 9.
Published in final edited form as: Cell. 2017 Feb 9;168(4):584–599. doi: 10.1016/j.cell.2016.12.015

Figure 1. Druggable Alterations in Oncology Today and in the Near Future.

Figure 1

The percent of patients by cancer type harboring a biomarker that, at present, guides the use of either FDA-approved or standard-of-care therapies (open circles) compared to the fraction of patients in the same tumor type harboring a genomic alteration with compelling clinical evidence that it predicts response to a drug but neither the genomic biomarker nor the drug are standard-of-care yet in that indication represented by an arrow.